These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19897852)

  • 1. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
    Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
    Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
    Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
    Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
    Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L
    Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
    Shi HZ; Tian J; Li CL
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
    Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
    Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
    Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
    Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
    Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
    Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
    Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R; Rawal S
    JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
    Szmit S; Langiewicz P; Złnierek J; Nurzyński P; Zaborowska M; Filipiak KJ; Opolski G; Szczylik C
    Kidney Blood Press Res; 2012; 35(1):18-25. PubMed ID: 21849795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.